Cargando…
Disease-modifying factors in hereditary angioedema: an RNA expression-based screening
BACKGROUND: Hereditary Angioedema due to C1-Inhibitor deficiency (HAE types I and II) is a monogenic disease characterized by sudden, self-limited episodes of cutaneous and mucosal swelling due to local deregulation of vascular permeability. Despite its monogenic pattern of inheritance, HAE exhibits...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671971/ https://www.ncbi.nlm.nih.gov/pubmed/23688356 http://dx.doi.org/10.1186/1750-1172-8-77 |
_version_ | 1782272054655975424 |
---|---|
author | López-Lera, Alberto Cabo, Fátima Sánchez Garrido, Sofía Dopazo, Ana López-Trascasa, Margarita |
author_facet | López-Lera, Alberto Cabo, Fátima Sánchez Garrido, Sofía Dopazo, Ana López-Trascasa, Margarita |
author_sort | López-Lera, Alberto |
collection | PubMed |
description | BACKGROUND: Hereditary Angioedema due to C1-Inhibitor deficiency (HAE types I and II) is a monogenic disease characterized by sudden, self-limited episodes of cutaneous and mucosal swelling due to local deregulation of vascular permeability. Despite its monogenic pattern of inheritance, HAE exhibits great clinical variability and low genotype/phenotype correlation among those affected, which ultimately hinders therapeutic approach and probably underlies yet unknown genetic and environmental factors. METHODS: We studied whole-genome RNA expression of PBMCs in three HAE type-I families (accounting for 40 individuals), 24 of which carry the same R472X mutation in the C1-Inhibitor gene and show large variability in terms of disease expression. Those included in this study were analyzed according to the presence of mutation and/or clinical symptoms. RESULTS: Instead of a single, common disease-associated expression pattern, we found different transcriptome signatures in two of the families studied. In one of them (referred to as DR family), symptoms correlate with the upregulation of 35 genes associated to the biological response to viral infections (including RSADs, OAS, MX and ISG pathway members) and immune response. In another pedigree (Q family), disease manifestation is linked to the upregulation of 43 genes with diverse functions, including transcription and protein folding. Moreover, symptoms-free members of the Q pedigree display relatively higher expression of 394 genes with a wide diversity of functions. CONCLUSION: We found no evidence for a common altered PBMC expression pattern linked to HAE symptoms in the three families analyzed. All the data considered, differential gene expression in PBMCs do not seem to play a significant role in the predisposition or protection against HAE in the basal -between crises- conditions analyzed. Although the RNA expression pattern associated to the response to viral infections observed in the DR family supports the idea of infectious diseases as a modifying factor for HAE severity, large-scale studies would be needed to statistically associate such expression pattern to the development of this rare disease. |
format | Online Article Text |
id | pubmed-3671971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36719712013-06-05 Disease-modifying factors in hereditary angioedema: an RNA expression-based screening López-Lera, Alberto Cabo, Fátima Sánchez Garrido, Sofía Dopazo, Ana López-Trascasa, Margarita Orphanet J Rare Dis Research BACKGROUND: Hereditary Angioedema due to C1-Inhibitor deficiency (HAE types I and II) is a monogenic disease characterized by sudden, self-limited episodes of cutaneous and mucosal swelling due to local deregulation of vascular permeability. Despite its monogenic pattern of inheritance, HAE exhibits great clinical variability and low genotype/phenotype correlation among those affected, which ultimately hinders therapeutic approach and probably underlies yet unknown genetic and environmental factors. METHODS: We studied whole-genome RNA expression of PBMCs in three HAE type-I families (accounting for 40 individuals), 24 of which carry the same R472X mutation in the C1-Inhibitor gene and show large variability in terms of disease expression. Those included in this study were analyzed according to the presence of mutation and/or clinical symptoms. RESULTS: Instead of a single, common disease-associated expression pattern, we found different transcriptome signatures in two of the families studied. In one of them (referred to as DR family), symptoms correlate with the upregulation of 35 genes associated to the biological response to viral infections (including RSADs, OAS, MX and ISG pathway members) and immune response. In another pedigree (Q family), disease manifestation is linked to the upregulation of 43 genes with diverse functions, including transcription and protein folding. Moreover, symptoms-free members of the Q pedigree display relatively higher expression of 394 genes with a wide diversity of functions. CONCLUSION: We found no evidence for a common altered PBMC expression pattern linked to HAE symptoms in the three families analyzed. All the data considered, differential gene expression in PBMCs do not seem to play a significant role in the predisposition or protection against HAE in the basal -between crises- conditions analyzed. Although the RNA expression pattern associated to the response to viral infections observed in the DR family supports the idea of infectious diseases as a modifying factor for HAE severity, large-scale studies would be needed to statistically associate such expression pattern to the development of this rare disease. BioMed Central 2013-05-20 /pmc/articles/PMC3671971/ /pubmed/23688356 http://dx.doi.org/10.1186/1750-1172-8-77 Text en Copyright © 2013 López-Lera et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research López-Lera, Alberto Cabo, Fátima Sánchez Garrido, Sofía Dopazo, Ana López-Trascasa, Margarita Disease-modifying factors in hereditary angioedema: an RNA expression-based screening |
title | Disease-modifying factors in hereditary angioedema: an RNA expression-based screening |
title_full | Disease-modifying factors in hereditary angioedema: an RNA expression-based screening |
title_fullStr | Disease-modifying factors in hereditary angioedema: an RNA expression-based screening |
title_full_unstemmed | Disease-modifying factors in hereditary angioedema: an RNA expression-based screening |
title_short | Disease-modifying factors in hereditary angioedema: an RNA expression-based screening |
title_sort | disease-modifying factors in hereditary angioedema: an rna expression-based screening |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671971/ https://www.ncbi.nlm.nih.gov/pubmed/23688356 http://dx.doi.org/10.1186/1750-1172-8-77 |
work_keys_str_mv | AT lopezleraalberto diseasemodifyingfactorsinhereditaryangioedemaanrnaexpressionbasedscreening AT cabofatimasanchez diseasemodifyingfactorsinhereditaryangioedemaanrnaexpressionbasedscreening AT garridosofia diseasemodifyingfactorsinhereditaryangioedemaanrnaexpressionbasedscreening AT dopazoana diseasemodifyingfactorsinhereditaryangioedemaanrnaexpressionbasedscreening AT lopeztrascasamargarita diseasemodifyingfactorsinhereditaryangioedemaanrnaexpressionbasedscreening |